



Receipt

TRANSMITTAL LETTER (General - Patent Pending)		Docket No. A003 US	
In Re Application Of: CHICHEPORTICHE, Yves; BROWNING, Jeffrey			
Serial No. 09/245/198	Filing Date 5 February 1999	Examiner	Group Art Unit
Title: A Tumor Necrosis Factor Related Ligand			
<p style="text-align: center;"><u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u></p> <p>Transmitted herewith is:</p> <p>A Communication to be filed in connection with the above-identified patent application with 3 attached Appendices; Power of Attorney from Jeffrey Browning; Postcard</p> <p>in the above identified application.</p> <p><input type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2327 as described below. A duplicate copy of this sheet is enclosed.</p> <p><input type="checkbox"/> Charge the amount of _____</p> <p><input checked="" type="checkbox"/> Credit any overpayment.</p> <p><input checked="" type="checkbox"/> Charge any additional fee required.</p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"><div style="text-align: center;"> _____ Signature</div><div style="text-align: center;">Dated: 6/30/99</div></div> <div style="margin-top: 20px;">Niki D. Cox, Esq. Reg. No. 42,446 BIOGEN, Inc.</div> <div style="margin-top: 20px;">07/21/1999 JARTIS 00000013 022327 09245198 01 Fx:576 25.00 CH</div>			
CC:		<div style="border: 1px solid black; padding: 5px;"><p>I certify that this document and fee is being deposited on June 30, 1999 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</p><div style="text-align: center;"> _____ Signature of Person Mailing Correspondence</div><div style="text-align: center; margin-top: 5px;">Laura McGuire _____ Typed or Printed Name of Person Mailing Correspondence</div></div>	


PROVISIONAL APPLICATION
FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS
60/023,541	08/07/96	\$150.00 A003P		5

KERRY A FLYNN
BIOGEN INC
14 CAMBRIDGE CENTER
CAMBRIDGE MA 02142



RECEIVED


OCT 1 1996

Biogen, Inc. - IP DEPT
REFERRED TO Jed/LML
NOTED BY hau

Receipt is acknowledged of this Provisional Application. This Provisional Application will not be examined for patentability. Be sure to provide the PROVISIONAL APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to Box Provisional Application within 10 days of receipt. Please provide a copy of the Provisional Application Filing Receipt with the changes noted thereon. This Provisional Application will automatically be abandoned twelve (12) months after its filing date and will not be subject to revival to restore it to pending status beyond a date which is after twelve (12) months from its filing date.

Applicant(s) YVES CHICHEPORTICHE, GENEVA, SWITZERLAND.

TITLE
TUMOR NECROSIS FACTOR FAMILY-RELATED PROTEIN



Docket No.: A003 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

CHICHEPORTICHE, Yves
BROWNING; Jeffrey

Examiner:

Group Art Unit:

Serial No.: 09/245,198


Filing Date: 5 February 1999

For: A Tumor Necrosis Factor Related Ligand

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

30 June 1999
Date


Laura M. McGuire

COMMUNICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Upon receipt of the official Filing Receipt for the above referenced application, a copy of which is attached hereto as Appendix A, the Applicant noticed that the Number and date for one of the Provisional Application is incorrect. The applicant hereby respectfully requests that Provisional Application "No. 60/023,451" and dated "08/02/96" be changed to "No. 60/023,541" and dated "08/07/96". A copy of the original Utility Patent Application Transmittal is attached as Appendix B. A copy of the original Provisional Application Filing Receipt is attached as Appendix C.


In view of the above remarks, the applicant submits that the above correction to the Filing Receipt is due in part to an error made by the applicant. Authorization is

hereby given to charge the fee as set forth under 37 CFR 1.19(h) of \$25.00 to Deposit Account No. 02-2327.

In addition, upon review of the file for this case, it was not clear whether the Power of Attorney signed by one of the inventors of the above referenced application, Jeffrey L. Browning, was enclosed with the applicants' May 20, 1999 response to Missing Parts. An executed Power of Attorney by Dr. Browning is therefore enclosed herewith.

Respectfully submitted,

Date: 6/30/99


Niki D. Cox, Esq.
Reg. No. 42, 446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)



APPENDIX A


FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/245,198	02/05/99	1643	\$2,080.00	A003	8	37	16

BIOGEN INC
14 CAMBRIDGE CENTER
CAMBRIDGE MA 02142



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

YVES CHICHEPORTICHE; JEFFREY J. BROWNING.

CONTINUING DATA AS CLAIMED BY APPLICANT- 541 08/07/96
PROVISIONAL APPLICATION NO. 60/023,451 08/02/96
PROVISIONAL APPLICATION NO. 60/028,515 10/18/96
PROVISIONAL APPLICATION NO. 60/040,820 03/18/97

FOREIGN APPLICATIONS- PCT PCT/US97/13945 08/01/97

FOREIGN FILING LICENSE GRANTED 02/22/99

TITLE

TUMOR NECROSIS FACTOR RELATED LIGAND

PRELIMINARY CLASS: 530


BIOGEN, INC-IP DEPT.	
MAR 2 1999	
REFERRED TO	KAF/NDC
NOTED BY	TC

Entered Computer

DATA ENTRY BY: SMITH, KAREN

TEAM: 04 DATE: 02/22/99


(see reverse)



APPENDIX B

UTILITY PATENT APPLICATION TRANSMITTAL

(Large Entity)



(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
A003

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

B x Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

Tumor Necrosis Factor Related Ligand

and invented by:

CHICHEPORTICHE, Yves and BROWNING, Jeffrey L.

Priority Applications check appropriate box and supply the requisite information:

07 august 1996 of prior application No.: **60/023,451**

18 October 1996 of prior application No.: **60/028,515**

18 March 1996 of prior application No.: **60/040,820**

07 August 1997 Priority application
PCT/US97/13945

Enclosed are:


Application Elements

1. ☐ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 47 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL

(Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))



Docket No.
A003

Total Pages in this Submission

Application Elements (Continued)

3. ☒ Drawings (when necessary as prescribed by 35 USC 113)
 - a. ☐ Formal Number of Sheets _____
 - b. ☒ Informal Number of Sheets 8
4. ☐ Oath or Declaration
 - a. ☐ Newly executed (original or copy) ☐ Unexecuted
 - b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
 - c. ☐ With Power of Attorney ☐ Without Power of Attorney
 - d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
 - a. ☐ Paper Copy
 - b. ☐ Computer Readable Copy (identical to computer copy)
 - c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
 - ☐ First Class ☒ Express Mail (Specify Label No.): EL272416768US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))


Docket No.
A003

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☐ Additional Enclosures (please identify below):



Fee Calculation and Transmittal


CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	35	- 20 =	15	x \$22.00	\$330.00
Indep. Claims	16	- 3 =	13	x \$82.00	\$1,066.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$790.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$2,186.00


- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2327 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$2,186.00 as filing fee.
 - ☒ Credit any overpayment.
 - ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated:

cc:


Signature
Warren A. Kaplan, Esq.
Reg. No. 34,199
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679 3598

APPENDIX C



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

POWER OF ATTORNEY

Docket No.

A003CIP

Name of Applicant: **BROWNING, Jeffrey L.**
Address of Applicant: **32 Milton Road**
Brookline, Massachusetts 02146

Title: **A Tumor Necrosis Factor Related Ligand**

Serial No., if Any: **09//245,198**

Filed: **5 February 1999**

TO THE ASSISTANT COMMISSIONER FOR PATENTS

The Assistant Commissioner for Patents
Washington, D.C. 20231

Honorable Sir:

I hereby appoint:


COX, Niki	42,446
FENTON, Gillian M.	36,508
FLYNN, Kerry A.	33,639
KAPLAN, Warren A.	34,199
NOE, Alphonse R.	25,603

as principal attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all future correspondence to:

Niki Cox
14 Cambridge Center
Cambridge, Massachusetts 02143
(617)679-2079
FAX: (617)679-2838

By:



Dated: 4.21.99

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.		
09/245,198	02/05/99	424	1633	A003		
APPLICANT	JEFFREY BROWNING, BROOKLINE, MA; YVES CHICHPORTICHE, GENEV, SWITZERLAND.					
	CONTINUING DOMESTIC DATA***					
	VERIFIED PROVISIONAL APPLICATION NO. 60/023,541 08/07/96					
	PROVISIONAL APPLICATION NO. 60/028,515 10/18/96					
PROVISIONAL APPLICATION NO. 60/040,820 03/18/97						
	371 (NAT'L STAGE) DATA***					
	VERIFIED					
	FOREIGN APPLICATIONS***					
	VERIFIED PCT PCT/US97/13945 08/07/97					
IF REQUIRED, FOREIGN FILING LICENSE GRANTED 02/22/99						
Foreign Priority claimed 35 USC 119 (a-d) conditions met		<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY MA	SHEETS DRAWING 8	TOTAL CLAIMS 37	INDEPENDENT CLAIMS 16
Verified and Acknowledged		Examiner's Initials	Initials			
ADDRESS	BIOGEN INC 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142					
	TUMOR NECROSIS FACTOR RELATED LIGAND					
TITLE						
FILING FEE RECEIVED	FEES: Authority has been given in Paper No. _____ to charge /cr dit DEPOSIT ACCOUNT NO. _____ for the following:			<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Proc ssing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		
\$2,210						